Stroke is a major public health problem, yet there is no treatment of proven value for widespread use in the acute phase of the illness. This paper outlines the rationale for using antiplatelet therapy in acute ischaemic stroke and why it appears to be one of the most promising agents for testing in very large scale clinical trials.